Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312571 | 0.88 | PIK3CD (0.32) | PIK3CDPOLB | |
| SCHEMBL22753191 | 0.82 | PER2 (0.32) | PER2 | |
| SCHEMBL22648379 | 0.81 | PIK3CD (0.36) | PIK3CDPOLBSMN1; SMN2LMNAMAPT | |
| SCHEMBL24175427 | 0.80 | PER2 (0.39) | PIK3CDPOLBGAASMN1; SMN2PER2 | |
| SCHEMBL24992646 | 0.80 | PIK3CD (0.58) | PIK3CDPOLBGAASMN1; SMN2PER2 | |
| SCHEMBL29947068 | 0.79 | SMN1; SMN2 (0.37) | PIK3CDPOLBGAASMN1; SMN2PER2 | |
| SCHEMBL21447030 | 0.77 | PIK3R1 (0.36) | PIK3CDPOLBGAASMN1; SMN2PER2 | |
| SCHEMBL13966498 | 0.77 | POLB (0.34) | POLB | |
| SCHEMBL9910033 | 0.75 | SMN1; SMN2 (0.45) | PIK3CDGAASMN1; SMN2PER2LMNA | |
| SCHEMBL13501652 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | PIK3CD 2677/4885POLB 4309/4885GAA 3068/4885 |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | PIK3CD 4774/4885POLB 419/4885GAA 283/4885 |
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PIK3CD 1521/4885POLB 3219/4885GAA 324/4885 |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | PIK3CD 3203/4885POLB 4443/4885GAA 344/4885 |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | F12, TFPI, F11 | PIK3CD 4058/4885POLB 3246/4885GAA 1109/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | PIK3CD 4774/4885POLB 419/4885GAA 283/4885 |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | RET, BRAF, FGFR3 | PIK3CD 869/4885POLB 3915/4885GAA 1822/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PIK3CD 1521/4885POLB 3219/4885GAA 324/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | PIK3CD 2677/4885POLB 4309/4885GAA 3068/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | PIK3CD 4774/4885POLB 419/4885GAA 283/4885 |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | PIK3CD 4265/4885POLB 3222/4885GAA 69/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | PIK3CD 4265/4885POLB 3222/4885GAA 69/4885 |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | PIK3CD 2636/4885POLB 3028/4885GAA 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.